Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 85

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 85
---
 warrants do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all the provisions of the warrant agreement and the warrant certificates relating to each series of warrants which we will file with the SEC and incorporate by reference as an exhibit to the registration statement of which this prospectus is a part at or prior to the time of the issuance of any series of warrants. General The applicable prospectus supplement will describe the terms of the warrants, including as applicable:

| • | the offering price; |

| • | the aggregate number or amount of underlying securities purchasable upon exercise of the warrants and the exercise price; |

| • | the number of warrants being offered; |

| • | the date, if any, after which the warrants and the underlying securities will be transferable separately; |

| • | the date on which the right to exercise the warrants will commence, and the date on which the right will expire, or the Expiration Date; |

| • | the number of warrants outstanding, if any; |

| • | any material Israeli and/or U.S. federal income tax consequences; |

| • | the terms, if any, on which we may accelerate the date by which the warrants must be exercised; and; |

| • | any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. |

Warrants will be offered and exercisable for U.S. dollars only and will be in registered form only. Holders of warrants will be able to exchange warrant certificates for new warrant certificates of different denominations, present warrants for registration of transfer, and exercise warrants at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Prior to the exercise of any warrants, holders of the warrants to purchase ordinary shares will not have any rights of holders of ordinary shares, including the right to receive payments of dividends, if any, or to exercise any applicable right to vote. Certain Risk Considerations Any warrants we issue will involve a degree of risk, including risks arising from fluctuations in the price of the underlying ordinary shares or debt securities and general risks applicable to the securities market (or markets) on which the underlying securities trade, as applicable. Prospective purchasers of the warrants will need to recognize that the warrants may expire worthless, and, thus, purchasers should be prepared to sustain a total loss of the purchase price of their warrants. This risk reflects the nature of a warrant as an asset that, other factors held